# LPOXY Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lpoxy-therapeutics

- Industry: Biotechnology
- Headquarters: Missouri, US
- Website: www.lpoxy.com/
- Total disclosed funding: $28M
- Latest round: Series A (Sep 8, 2025)
- Investors on record: 1

## About

LPOXY Therapeutics, Inc. is a US-based biopharmaceutical company focused on developing innovative therapies to prevent antibiotic-induced Clostridioides difficile colitis, addressing a significant public health concern.Founded in 2020, LPOXY Therapeutics, Inc. specializes in therapeutic innovations for antibiotic-related infections. The company has engaged in a pivotal strategy to enhance its operational focus on SIDIPREV™, a preventive oral medication. The firm is not known to have any parent companies or subsidiaries.LPOXY Therapeutics is primarily focused on the development of SIDIPREV™, an innovative oral medication designed to prevent antibiotic-induced Clostridioides difficile (C. difficile) colitis. This clinical-stage therapy aims to address the urgent public health challenge posed by this superinfection by increasing oxygen tension in the colon during antibiotic treatment. Targeting patients undergoing antibiotic therapy and those with inflammatory bowel diseases, SIDIPREV™ is positioned as a preventative measure in healthcare settings, particularly in the US, where C. difficile colitis presents substantial challenges.LPOXY Therapeutics generates revenue through strategic partnerships and potential distribution agreements for SIDIPREV™. The company aims to collaborate with healthcare providers and pharmaceutical distributors to ensure access to its therapeutic product, utilizing a business-to-business model for wider distribution. While specific pricing details have not been disclosed, the company plans to align its pricing with industry standards to facilitate accessibility for healthcare facilities.In September 2025, LPOXY Therapeutics, Inc. raised USD 28 million in series A funding from new investor 5 Horizons Ventures. The company plans to utilize these funds to establish an investment syndicate aimed at financing its registrational STOP-Cdiff clinical trial. Additionally, LPOXY Therapeutics is focusing on enhancing its product offerings and expanding its market presence, although specific new products or geographic regions targeted for expansion have not been detailed.

## Funding rounds

- Series A, Sep 8, 2025, $28M — 5 Horizons Ventures

## Investors

- 5 Horizons Ventures (https://capitalatlas.ai/funds/5-horizons-ventures) — Series A